近年来乳腺癌、卵巢癌、胰腺癌等实体瘤的发病率逐年增加,临床上还缺乏有效的治疗药物。作为第1个用于人类癌症疗法的聚腺苷二磷酸核糖聚合酶(PARP)抑制剂,临床前研究表明rucaparib可明显抑制乳腺癌、卵巢癌等实体瘤。临床研究显示rucaparib具有良好的安全性和有效性。主要从rucaparib的药物概况、相关背景、合成路线、临床前研究和临床研究方面进行介绍。

Recently, the morbidity of breast cancer, ovarian cancer, pancreatic cancer, and other solid tumors has increased year by year, and there is still lack of effective drugs in clinic. As the first poly ADP-ribose polymerase inhibitor for human cancer therapy, preclinical studies show that rucaparib can significantly inhibit breast cancer, ovarian cancer, and other solid tumors. Clinical studies show that rucaparib has good safety and effectiveness. The drug situation, background, route of synthesis, preclinical, and clinical trials researches of rucaparib are reviewed in this paper.